News Katie Matt 3/4/25 News Katie Matt 3/4/25 Boosting CAR T-cell Efficacy to Increase Cancer Cure Rates Read More News Katie Matt 2/21/24 News Katie Matt 2/21/24 Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies Read More News Katie Matt 8/8/23 News Katie Matt 8/8/23 Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001 Read More Publication Rhodesia Jackson 5/11/23 Publication Rhodesia Jackson 5/11/23 ALETA-001, a CAR-T Engager protein, or CTE, optimizes anti-CD19 CAR-T celltherapies for lymphoma Read More News Rhodesia Jackson 11/7/22 News Rhodesia Jackson 11/7/22 Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001 Read More News Rhodesia Jackson 6/23/21 News Rhodesia Jackson 6/23/21 Aleta Biotherapeutics and Cancer Research UK collaborate to advance blood cancer therapy into the clinic Read More Publication Rhodesia Jackson 4/28/19 Publication Rhodesia Jackson 4/28/19 A CD19-Anti-ErbB2 scFv Engager Protein EnablesCD19-Specific CAR T Cells to Eradicate ErbB2+ Solid Cancer Read More Publication Rhodesia Jackson 4/28/19 Publication Rhodesia Jackson 4/28/19 CAR T Engager proteins optimize anti CD19 CAR T cell therapies for lymphoma Read More Publication Rhodesia Jackson 4/27/19 Publication Rhodesia Jackson 4/27/19 Anti-CD19 CAR T cells potently redirected to kill solid tumor cells Read More Publication Rhodesia Jackson 4/26/19 Publication Rhodesia Jackson 4/26/19 Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo Read More
News Katie Matt 3/4/25 News Katie Matt 3/4/25 Boosting CAR T-cell Efficacy to Increase Cancer Cure Rates Read More
News Katie Matt 2/21/24 News Katie Matt 2/21/24 Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies Read More
News Katie Matt 8/8/23 News Katie Matt 8/8/23 Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001 Read More
Publication Rhodesia Jackson 5/11/23 Publication Rhodesia Jackson 5/11/23 ALETA-001, a CAR-T Engager protein, or CTE, optimizes anti-CD19 CAR-T celltherapies for lymphoma Read More
News Rhodesia Jackson 11/7/22 News Rhodesia Jackson 11/7/22 Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001 Read More
News Rhodesia Jackson 6/23/21 News Rhodesia Jackson 6/23/21 Aleta Biotherapeutics and Cancer Research UK collaborate to advance blood cancer therapy into the clinic Read More
Publication Rhodesia Jackson 4/28/19 Publication Rhodesia Jackson 4/28/19 A CD19-Anti-ErbB2 scFv Engager Protein EnablesCD19-Specific CAR T Cells to Eradicate ErbB2+ Solid Cancer Read More
Publication Rhodesia Jackson 4/28/19 Publication Rhodesia Jackson 4/28/19 CAR T Engager proteins optimize anti CD19 CAR T cell therapies for lymphoma Read More
Publication Rhodesia Jackson 4/27/19 Publication Rhodesia Jackson 4/27/19 Anti-CD19 CAR T cells potently redirected to kill solid tumor cells Read More
Publication Rhodesia Jackson 4/26/19 Publication Rhodesia Jackson 4/26/19 Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo Read More
